Methohexital
Methohexital Brand names, Methohexital Analogs
Methohexital Brand Names Mixture
- No information avaliable
Methohexital Chemical_Formula
C14H18N2O3
Methohexital RX_link
http://www.rxlist.com/cgi/generic3/methohexital.htm
Methohexital fda sheet
Methohexital msds (material safety sheet)
Methohexital Synthesis Reference
No information avaliable
Methohexital Molecular Weight
262.304 g/mol
Methohexital Melting Point
No information avaliable
Methohexital H2O Solubility
No information avaliable
Methohexital State
Solid
Methohexital LogP
1.724
Methohexital Dosage Forms
Powder for solution
Methohexital Indication
Indicated for use as an intravenous anaesthetic.
Methohexital Pharmacology
Methohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Methohexital Absorption
The absolute bioavailability following rectal administration of methohexital is 17%.
Methohexital side effects and Toxicity
The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
Methohexital Patient Information
When appropriate, patients should be instructed as to the hazards of drowsiness that may follow use of barbiturates. Outpatients should be released in the company of another individual, and no skilled activities, such as operating machinery or driving a motor vehicle, should be engaged in for 8 to 12 hours.
Methohexital Organisms Affected
Humans and other mammals
